Pub Date : 2024-04-11DOI: 10.14302/issn.2693-1176.ijgh-24-5036
Tamie Saeki
According to the Japan’s National Health and Nutrition Survey, trends in the intake of vegetables and fruits (1999-2018), which are considered effective in preventing lifestyle-related diseases, are far below the target value; In the under-50 age group, less than 30% achieved the target vegetable intake of 350g, and less than 15% achieved the target fruit intake of 200g 53. Against such background, it has become a challenge to nurture children's ‘self-management ability’ that leads to spontaneous and healthy dietary habits 16. Until now, almost all research on ‘Dietary education’ has been conducted in the field of nutrition, focusing on accumulating nutritional knowledge by explaining each nutritional component and its function. However, it is difficult to nurture spontaneous and healthy dietary habits simply through repeated nutrition-based education. It can be said that the pedagogical approach of this paper has made it possible to pursue from a broader perspective that influences food choices. Research on ‘nutrition transition’ points out “worldwide obesity dynamics and their determinants” based on “a shift in the broader patterns of dietary habits (Western-style diet) and corresponding nutrition-related diseases” 42. Nutrition transition research 50, 40 has a broad and holistic perspective on food and health, making it easy to understand nutrition. The purpose of this paper is to pursue how to nurture the ‘self-management ability’ for spontaneous and healthy dietary habits, based on these latest nutritional knowledges. Because nutrition transition is a global phenomenon, the author choses to use broader methods of international comparative research. Comparisons lead to discoveries and value creation. This can be said to have the greatest significance in comparative research.
{"title":"Comparative Study On ‘Dietary Education’ In Japan And Korea: From The Latest Nutritional Knowledge Perspective","authors":"Tamie Saeki","doi":"10.14302/issn.2693-1176.ijgh-24-5036","DOIUrl":"https://doi.org/10.14302/issn.2693-1176.ijgh-24-5036","url":null,"abstract":"According to the Japan’s National Health and Nutrition Survey, trends in the intake of vegetables and fruits (1999-2018), which are considered effective in preventing lifestyle-related diseases, are far below the target value; In the under-50 age group, less than 30% achieved the target vegetable intake of 350g, and less than 15% achieved the target fruit intake of 200g 53.\u0000\u0000Against such background, it has become a challenge to nurture children's ‘self-management ability’ that leads to spontaneous and healthy dietary habits 16. Until now, almost all research on ‘Dietary education’ has been conducted in the field of nutrition, focusing on accumulating nutritional knowledge by explaining each nutritional component and its function.\u0000\u0000However, it is difficult to nurture spontaneous and healthy dietary habits simply through repeated nutrition-based education. It can be said that the pedagogical approach of this paper has made it possible to pursue from a broader perspective that influences food choices.\u0000\u0000Research on ‘nutrition transition’ points out “worldwide obesity dynamics and their determinants” based on “a shift in the broader patterns of dietary habits (Western-style diet) and corresponding nutrition-related diseases” 42. Nutrition transition research 50, 40 has a broad and holistic perspective on food and health, making it easy to understand nutrition. The purpose of this paper is to pursue how to nurture the ‘self-management ability’ for spontaneous and healthy dietary habits, based on these latest nutritional knowledges.\u0000\u0000Because nutrition transition is a global phenomenon, the author choses to use broader methods of international comparative research. Comparisons lead to discoveries and value creation. This can be said to have the greatest significance in comparative research.","PeriodicalId":517106,"journal":{"name":"International Journal of Global Health","volume":"79 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140713009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background Cancer and diabetes are risk factors for COVID-19 mortality rates. Remdesivir, dexamethasone, and vaccines are used to improve clinical outcomes. We aimed to evaluate the factors associated with COVID-19 mortality rates. Methods This retrospective study enrolled moderate to critical COVID-19 patients. The index day was the day of the COVID-19 diagnosis. Patients were followed up until either death or discharge. A two-way analysis of variance examined the interaction between independent mortality risk factors. Results A total of 205 patients were analyzed, and the mortality rate was 29.5% (n=60/205). The cumulative survival rate was significantly lower in patients with a CCI score ≥ 6, cancer, and diabetes. In multivariate analysis, critical illness, cancer, diabetes, chronic liver disease, a CCI score ≥ 6, unvaccinated, and early use of remdesivir/dexamethasone were independent risk factors for mortality. The onset of remdesivir/dexamethasone ≥ 2 days and < 3 doses of vaccinations were higher mortality rate, with its impact being more significant amongst patients with cancer/diabetes, compared to those without cancer/diabetes (p for interaction = 0.046/0.049, 0.060/0.042, and 0.038/0.048 respectively). Conclusions COVID-19 vaccination ≥ 3 doses and early administration of remdesivir and dexamethasone can significantly reduce mortality rates, particularly in patients with cancer or diabetes.
背景癌症和糖尿病是导致 COVID-19 死亡率的危险因素。雷米替韦、地塞米松和疫苗被用于改善临床结果。我们旨在评估与 COVID-19 死亡率相关的因素。指标日为确诊 COVID-19 的当天。对患者进行随访，直至死亡或出院。结果共分析了205名患者，死亡率为29.5%（n=60/205）。CCI评分≥6分、癌症和糖尿病患者的累积存活率明显较低。在多变量分析中，危重病、癌症、糖尿病、慢性肝病、CCI评分≥6、未接种疫苗和早期使用雷米地韦/地塞米松是导致死亡的独立风险因素。开始使用雷米地韦/地塞米松≥2天和接种疫苗次数<3次的患者死亡率较高，与未患癌症/糖尿病的患者相比，雷米地韦/地塞米松对癌症/糖尿病患者的影响更为显著（交互作用 p = 0.结论COVID-19疫苗接种≥3剂和早期服用雷米替韦和地塞米松可显著降低死亡率，尤其是癌症或糖尿病患者的死亡率。
{"title":"Stratified Analysis of Factors Associated With Mortality in Patients With COVID-19 Based on Cancer and Diabetes","authors":"Ya-Chun Liao, Hsin-Hua Chen, Po-Yu Liu, Zhi-Yuan Shi, Yu-Hui Lin, Che-An Tsai, Yung-Chun Chen, Chien-Hao Tseng, Chia-Wei Liu, Tzu-Hua Wu, Ming-Ju Wu, S. Lin","doi":"10.14302/issn.2693-1176.ijgh-23-4879","DOIUrl":"https://doi.org/10.14302/issn.2693-1176.ijgh-23-4879","url":null,"abstract":"Background\u0000Cancer and diabetes are risk factors for COVID-19 mortality rates. Remdesivir, dexamethasone, and vaccines are used to improve clinical outcomes. We aimed to evaluate the factors associated with COVID-19 mortality rates.\u0000\u0000Methods\u0000This retrospective study enrolled moderate to critical COVID-19 patients. The index day was the day of the COVID-19 diagnosis. Patients were followed up until either death or discharge. A two-way analysis of variance examined the interaction between independent mortality risk factors.\u0000\u0000Results\u0000A total of 205 patients were analyzed, and the mortality rate was 29.5% (n=60/205). The cumulative survival rate was significantly lower in patients with a CCI score ≥ 6, cancer, and diabetes. In multivariate analysis, critical illness, cancer, diabetes, chronic liver disease, a CCI score ≥ 6, unvaccinated, and early use of remdesivir/dexamethasone were independent risk factors for mortality. The onset of remdesivir/dexamethasone ≥ 2 days and < 3 doses of vaccinations were higher mortality rate, with its impact being more significant amongst patients with cancer/diabetes, compared to those without cancer/diabetes (p for interaction = 0.046/0.049, 0.060/0.042, and 0.038/0.048 respectively).\u0000\u0000Conclusions\u0000COVID-19 vaccination ≥ 3 doses and early administration of remdesivir and dexamethasone can significantly reduce mortality rates, particularly in patients with cancer or diabetes.","PeriodicalId":517106,"journal":{"name":"International Journal of Global Health","volume":"28 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139896479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background Cancer and diabetes are risk factors for COVID-19 mortality rates. Remdesivir, dexamethasone, and vaccines are used to improve clinical outcomes. We aimed to evaluate the factors associated with COVID-19 mortality rates. Methods This retrospective study enrolled moderate to critical COVID-19 patients. The index day was the day of the COVID-19 diagnosis. Patients were followed up until either death or discharge. A two-way analysis of variance examined the interaction between independent mortality risk factors. Results A total of 205 patients were analyzed, and the mortality rate was 29.5% (n=60/205). The cumulative survival rate was significantly lower in patients with a CCI score ≥ 6, cancer, and diabetes. In multivariate analysis, critical illness, cancer, diabetes, chronic liver disease, a CCI score ≥ 6, unvaccinated, and early use of remdesivir/dexamethasone were independent risk factors for mortality. The onset of remdesivir/dexamethasone ≥ 2 days and < 3 doses of vaccinations were higher mortality rate, with its impact being more significant amongst patients with cancer/diabetes, compared to those without cancer/diabetes (p for interaction = 0.046/0.049, 0.060/0.042, and 0.038/0.048 respectively). Conclusions COVID-19 vaccination ≥ 3 doses and early administration of remdesivir and dexamethasone can significantly reduce mortality rates, particularly in patients with cancer or diabetes.
背景癌症和糖尿病是导致 COVID-19 死亡率的危险因素。雷米替韦、地塞米松和疫苗被用于改善临床结果。我们旨在评估与 COVID-19 死亡率相关的因素。指标日为确诊 COVID-19 的当天。对患者进行随访，直至死亡或出院。结果共分析了205名患者，死亡率为29.5%（n=60/205）。CCI评分≥6分、癌症和糖尿病患者的累积存活率明显较低。在多变量分析中，危重病、癌症、糖尿病、慢性肝病、CCI评分≥6、未接种疫苗和早期使用雷米地韦/地塞米松是导致死亡的独立风险因素。开始使用雷米地韦/地塞米松≥2天和接种疫苗次数<3次的患者死亡率较高，与未患癌症/糖尿病的患者相比，雷米地韦/地塞米松对癌症/糖尿病患者的影响更为显著（交互作用 p = 0.结论COVID-19疫苗接种≥3剂和早期服用雷米替韦和地塞米松可显著降低死亡率，尤其是癌症或糖尿病患者的死亡率。
{"title":"Stratified Analysis of Factors Associated With Mortality in Patients With COVID-19 Based on Cancer and Diabetes","authors":"Ya-Chun Liao, Hsin-Hua Chen, Po-Yu Liu, Zhi-Yuan Shi, Yu-Hui Lin, Che-An Tsai, Yung-Chun Chen, Chien-Hao Tseng, Chia-Wei Liu, Tzu-Hua Wu, Ming-Ju Wu, S. Lin","doi":"10.14302/issn.2693-1176.ijgh-23-4879","DOIUrl":"https://doi.org/10.14302/issn.2693-1176.ijgh-23-4879","url":null,"abstract":"Background\u0000Cancer and diabetes are risk factors for COVID-19 mortality rates. Remdesivir, dexamethasone, and vaccines are used to improve clinical outcomes. We aimed to evaluate the factors associated with COVID-19 mortality rates.\u0000\u0000Methods\u0000This retrospective study enrolled moderate to critical COVID-19 patients. The index day was the day of the COVID-19 diagnosis. Patients were followed up until either death or discharge. A two-way analysis of variance examined the interaction between independent mortality risk factors.\u0000\u0000Results\u0000A total of 205 patients were analyzed, and the mortality rate was 29.5% (n=60/205). The cumulative survival rate was significantly lower in patients with a CCI score ≥ 6, cancer, and diabetes. In multivariate analysis, critical illness, cancer, diabetes, chronic liver disease, a CCI score ≥ 6, unvaccinated, and early use of remdesivir/dexamethasone were independent risk factors for mortality. The onset of remdesivir/dexamethasone ≥ 2 days and < 3 doses of vaccinations were higher mortality rate, with its impact being more significant amongst patients with cancer/diabetes, compared to those without cancer/diabetes (p for interaction = 0.046/0.049, 0.060/0.042, and 0.038/0.048 respectively).\u0000\u0000Conclusions\u0000COVID-19 vaccination ≥ 3 doses and early administration of remdesivir and dexamethasone can significantly reduce mortality rates, particularly in patients with cancer or diabetes.","PeriodicalId":517106,"journal":{"name":"International Journal of Global Health","volume":"149 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139893402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：